Item | Group | Pre-treatment | 6 months pro-treatment | 1 year pro-treatment | t | P |
BMD | A | −2.96 ± 0.18 | −2.94 ± 0.17a | −2.62 ± 0.20b | −1.45/−8.52 | 0.16 a/<0.05 b |
(SD) | B | −2.94 ± 0.22 | −2.90 ± 0.23a | −2.32 ± 0.19b | −1.83/−0.29 | 0.08 a/<0.05 b |
| C | −2.96 ± 0.19 | −2.92 ± 0.20a | −2.06 ± 0.23b | −1.93/−9.80 | 0.06 a/<0.05 b |
PINP | A | 58.57 ± 1.68 | 44.83 ± 12.35a | 43.10 ± 10.62b | −12.38/−13.42 | <0.05 a/<0.05 b |
(g/L) | B | 59.76 ± 1.83 | 72.34 ± 15.16a | 68.73 ± 13.72b | 9.89/5.34 | <0.05 a/<0.05 b |
| C | 58.85 ± 1.83 | 65.74 ± 8.98a | 64.23 ± 14.61b | 6.72/5.89 | <0.05 a/<0.05 b |
β- | A | 0.55 ± 0.32 | 0.29 ± 0.08a | 0.26 ± 0.13b | −0.32/−0.35 | <0.05 a/<0.05 b |
CTX | B | 0.53 ± 0.19 | 0.43 ± 0.12a | 0.38 ± 0.21b | −0.13/−0.16 | <0.05 a/<0.05 b |
(g/L) | C | 0.54 ± 0.24 | 0.39 ± 0.31a | 0.32 ± 0.14b | −0.19/−0.21 | <0.05 a/<0.05 b |